Low-dose Interleukin-2 and Rapamycin on sjögren's Syndrome
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this paper is to analysis of therapeutic effect and immunological mechanism of
low-dose IL-2 combined with rapamycin in the treatment of Sjogren's syndrome